Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of OVX033 Vaccine in Healthy Subjects
NCT06128382Phase 1Completed
- Sponsor
- Osivax
- Start
- Jan 2024
- Primary completion
- Jul 2024
- Modality
- Nanoparticles, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OVX033 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Osivax. Primary endpoints: Solicited local and systemic signs and symptoms at 7 days, Unsolicited adverse events at 29 days and 4 more. Started Jan 2024; status: completed.
02
Drugs
OVX033
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06128382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128382.